Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Novo Nordisk licenses 'small antibody' tech from Ablynx

Ablynx has licensed its nanobody platform to Novo Nordisk which hopes to discover and develop single-domain antibody fragment drug candidates.

Reprocell buys into cell therapy discovery services sector with Biopta takeover

Reprocell has entered the CRO space through the acquisition of preclinical discovery services Biopta.

Samsung Bioepis bolstered by EMA recommendation of Enbrel biosimilar

The EMA has given the thumbs up to Benepali, a biosimilar of Amgen’s Enbrel developed by Samsung Bioepis, a JV between Biogen and Samsung Biologics.

Abzena to buy TCRS in latest boost to its ADC offering

Abzena is set to buy The Chemistry Research Solution (TCRS) in a deal one analyst says shows the firm’s intentions to dominate the bio-conjugation space.

CRISPR editing gives mosquitoes malaria-resistant DNA

Scientists trying to curb malaria deaths usually concentrate on preventing mosquito bites or developing human vaccines and therapies, but novel gene-editing tool CRISPR is opening up another path.

Filgrastim biosimilar is first Latin copy biologic, says Brazil

Brazilian company Eurofarma claims it has developed Latin America’s first home-grown biosimilar.

Abcam buys AxioMx for antibody production technology

Abcam has acquired monoclonal antibody production specialist AxioMx in a deal worth up to $45m (€42m).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...